JAK1 and Hutchinson-Gilford progeria syndrome: Importantly, BAR, a well-established JAK1/2 inhibitor with a favorable safety profile [68], offers a complementary approach by targeting systemic inflammation, which is a hallmark of HGPS [69,70].